Acute renal toxicity and its detection by the Yellow card reporting scheme

K. Davidson, S. Kerr, Moira Kinnear, D.N. Bateman

Research output: Contribution to journalConference Contribution

Abstract

Paper presented at the United Kingdom Clinical Pharmacy Association (UKCPA) autumn symposium, Hinckley, 18-20 Nov 2011 (Oral Communication OC 4).
The aim of this study was to describe frequency and profile of reporters of yellow card (YC) reports for renal toxicities in Scotland and the UK, and to identify which drugs are reported and at what frequency and to identify risk factors for drug induced renal toxicity.
Data were obtained through a retrospective analysis of the UK YC database from 2002 to 2006 using specified renal urinary Medical Dictionary of Regulatory Activities (MedDRA) terms to identify relevant yellow card reports. In the UK, 1484 (2.2%) yellow cards were received by the MHRA for the specified MedDRA terms compared to 152 (2.4%) for Scotland. In each case, the top three drug classes implicated were NSAIDs, drugs affecting the renin-angiotensin system and lipid-lowering agents. Comparison of reporting by different healthcare professionals showed a comparable split between GPs, hospital doctors and hospital pharmacists.
LanguageEnglish
PagesS11-S12
Number of pages2
JournalClinical Pharmacist
Volume4
Issue numberApril (Supplement 2)
Publication statusPublished - Apr 2012
EventUnited Kingdom Clinical Pharmacy Association autumn symposium 2011 - Hinckley, United Kingdom
Duration: 18 Nov 201120 Nov 2011

Fingerprint

Toxicity
Medical Dictionaries
Kidney
Scotland
Glossaries
Pharmaceutical Preparations
Angiotensins
Non-Steroidal Anti-Inflammatory Agents
Renin-Angiotensin System
Pharmacists
Renin
Communication
Databases
Delivery of Health Care
Lipids

Keywords

  • adverse effects
  • united kingdom
  • scotland
  • kidney
  • adverse reaction reporting
  • acute
  • renal toxicity
  • detection
  • yellow card
  • reporting
  • scheme

Cite this

Davidson, K., Kerr, S., Kinnear, M., & Bateman, D. N. (2012). Acute renal toxicity and its detection by the Yellow card reporting scheme. Clinical Pharmacist, 4(April (Supplement 2)), S11-S12.
Davidson, K. ; Kerr, S. ; Kinnear, Moira ; Bateman, D.N. . / Acute renal toxicity and its detection by the Yellow card reporting scheme. In: Clinical Pharmacist. 2012 ; Vol. 4, No. April (Supplement 2). pp. S11-S12.
@article{69446afc3ecd4edf80a52380b880b28e,
title = "Acute renal toxicity and its detection by the Yellow card reporting scheme",
abstract = "Paper presented at the United Kingdom Clinical Pharmacy Association (UKCPA) autumn symposium, Hinckley, 18-20 Nov 2011 (Oral Communication OC 4). The aim of this study was to describe frequency and profile of reporters of yellow card (YC) reports for renal toxicities in Scotland and the UK, and to identify which drugs are reported and at what frequency and to identify risk factors for drug induced renal toxicity. Data were obtained through a retrospective analysis of the UK YC database from 2002 to 2006 using specified renal urinary Medical Dictionary of Regulatory Activities (MedDRA) terms to identify relevant yellow card reports. In the UK, 1484 (2.2{\%}) yellow cards were received by the MHRA for the specified MedDRA terms compared to 152 (2.4{\%}) for Scotland. In each case, the top three drug classes implicated were NSAIDs, drugs affecting the renin-angiotensin system and lipid-lowering agents. Comparison of reporting by different healthcare professionals showed a comparable split between GPs, hospital doctors and hospital pharmacists.",
keywords = "adverse effects, united kingdom, scotland, kidney, adverse reaction reporting, acute, renal toxicity, detection, yellow card , reporting, scheme",
author = "K. Davidson and S. Kerr and Moira Kinnear and D.N. Bateman",
year = "2012",
month = "4",
language = "English",
volume = "4",
pages = "S11--S12",
journal = "Clinical Pharmacist",
issn = "1758-9061",
number = "April (Supplement 2)",

}

Davidson, K, Kerr, S, Kinnear, M & Bateman, DN 2012, 'Acute renal toxicity and its detection by the Yellow card reporting scheme' Clinical Pharmacist, vol. 4, no. April (Supplement 2), pp. S11-S12.

Acute renal toxicity and its detection by the Yellow card reporting scheme. / Davidson, K. ; Kerr, S. ; Kinnear, Moira; Bateman, D.N. .

In: Clinical Pharmacist, Vol. 4, No. April (Supplement 2), 04.2012, p. S11-S12.

Research output: Contribution to journalConference Contribution

TY - JOUR

T1 - Acute renal toxicity and its detection by the Yellow card reporting scheme

AU - Davidson, K.

AU - Kerr, S.

AU - Kinnear, Moira

AU - Bateman, D.N.

PY - 2012/4

Y1 - 2012/4

N2 - Paper presented at the United Kingdom Clinical Pharmacy Association (UKCPA) autumn symposium, Hinckley, 18-20 Nov 2011 (Oral Communication OC 4). The aim of this study was to describe frequency and profile of reporters of yellow card (YC) reports for renal toxicities in Scotland and the UK, and to identify which drugs are reported and at what frequency and to identify risk factors for drug induced renal toxicity. Data were obtained through a retrospective analysis of the UK YC database from 2002 to 2006 using specified renal urinary Medical Dictionary of Regulatory Activities (MedDRA) terms to identify relevant yellow card reports. In the UK, 1484 (2.2%) yellow cards were received by the MHRA for the specified MedDRA terms compared to 152 (2.4%) for Scotland. In each case, the top three drug classes implicated were NSAIDs, drugs affecting the renin-angiotensin system and lipid-lowering agents. Comparison of reporting by different healthcare professionals showed a comparable split between GPs, hospital doctors and hospital pharmacists.

AB - Paper presented at the United Kingdom Clinical Pharmacy Association (UKCPA) autumn symposium, Hinckley, 18-20 Nov 2011 (Oral Communication OC 4). The aim of this study was to describe frequency and profile of reporters of yellow card (YC) reports for renal toxicities in Scotland and the UK, and to identify which drugs are reported and at what frequency and to identify risk factors for drug induced renal toxicity. Data were obtained through a retrospective analysis of the UK YC database from 2002 to 2006 using specified renal urinary Medical Dictionary of Regulatory Activities (MedDRA) terms to identify relevant yellow card reports. In the UK, 1484 (2.2%) yellow cards were received by the MHRA for the specified MedDRA terms compared to 152 (2.4%) for Scotland. In each case, the top three drug classes implicated were NSAIDs, drugs affecting the renin-angiotensin system and lipid-lowering agents. Comparison of reporting by different healthcare professionals showed a comparable split between GPs, hospital doctors and hospital pharmacists.

KW - adverse effects

KW - united kingdom

KW - scotland

KW - kidney

KW - adverse reaction reporting

KW - acute

KW - renal toxicity

KW - detection

KW - yellow card

KW - reporting

KW - scheme

UR - http://www.pjonline.com/files/rps-pjonline/CP,%20Apr,%20pS1-S49,%20UKCPA%20abstracts%20print.pdf

UR - http://www.ukcpa.net/

M3 - Conference Contribution

VL - 4

SP - S11-S12

JO - Clinical Pharmacist

T2 - Clinical Pharmacist

JF - Clinical Pharmacist

SN - 1758-9061

IS - April (Supplement 2)

ER -

Davidson K, Kerr S, Kinnear M, Bateman DN. Acute renal toxicity and its detection by the Yellow card reporting scheme. Clinical Pharmacist. 2012 Apr;4(April (Supplement 2)):S11-S12.